Alfresa Holdings Corporation (TSE: 2784), Japan's leading pharmaceutical distribution group, reported FY2026 (year ended March 31, 2026) consolidated results under Japanese GAAP that showed diverging trends between the top line and operating profitability. Net sales rose 4.8% year-on-year to ¥3,104.1 billion, while operating profit declined 5.0% to ¥36.2 billion and ordinary profit eased 4.6% to ¥38.6 billion. However, profit attributable to owners of the parent surged 52.4% to ¥41.7 billion from ¥27.4 billion the prior year, boosted by non-recurring below-the-line items. Basic earnings per share rose to ¥229.64 from ¥147.54.
The wholesale pharmaceutical distribution segment, which dominates the group, benefited from volume growth across hospital, clinic and dispensing-pharmacy channels as Japan's aging population continued to drive medicine consumption. Revenue growth of approximately 5% reflects both underlying demand and inflationary repricing of some generic and specialty drug categories. However, the operating margin remained thin at around 1.2%, consistent with the structurally low-margin nature of pharma wholesale, and fell from 1.3% the prior year as logistics and personnel costs increased.
One-off gains inflate net profit; operating pressure persists
The 52.4% surge in net profit to ¥41.7 billion was driven by extraordinary and below-the-line items rather than core business improvement. Operating profit of ¥36.2 billion was actually ¥1.9 billion below the prior year's ¥38.1 billion, reflecting continued margin compression in distribution. Ordinary profit of ¥38.6 billion similarly declined 4.6% year-on-year. The divergence between ordinary and net profit — a gap of ¥3.1 billion — indicates meaningful extraordinary income recognized in the period, though specifics beyond the headline figures were not detailed in the tanshin. Comprehensive income for the year grew 54.7% to ¥39.3 billion.
Balance sheet strengthens; cash flow generation rebounds
Total assets grew to ¥1,507.0 billion from ¥1,439.9 billion, and net assets expanded to ¥507.9 billion from ¥482.2 billion. The equity ratio improved marginally to 33.7% from 33.5%, and book value per share increased to ¥2,792.01 from ¥2,650.27. Cash flow from operations rebounded sharply to ¥38.6 billion from just ¥5.6 billion in FY2025, a significant improvement reflecting better working-capital management in pharmaceutical inventory and receivables. Free cash flow (operating less investing) turned strongly positive at approximately ¥29.8 billion, compared with a negative ¥19.3 billion in the prior year.
Dividend raised; FY2027 guidance signals 50% profit drop
The full-year dividend was raised to ¥68.00 per share (¥34.00 interim + ¥34.00 year-end), up from ¥63.00 in FY2025, with a payout ratio of 29.6%. For FY2027 (ending March 2027), Alfresa guided for a further lift to ¥71.00 per share. However, the earnings guidance is materially weaker: FY2027 net profit is guided at just ¥20.8 billion, a steep 50.2% decline from FY2026's elevated base. Operating profit is guided at ¥33.9 billion (−6.3%) and ordinary profit at ¥36.6 billion (−5.3%), implying the normalisation of the one-off items that inflated FY2026 net profit. Half-year (H1 FY2027) guidance is for operating profit of ¥13.3 billion (−17.9%) and net profit of ¥7.9 billion (−31.4%).
| Metric | FY2026 | FY2025 | YoY |
|---|---|---|---|
| Net sales (¥ billion) | 3,104.1 | 2,961.1 | +4.8% |
| Operating profit (¥ billion) | 36.2 | 38.1 | −5.0% |
| Ordinary profit (¥ billion) | 38.6 | 40.5 | −4.6% |
| Net profit attrib. to owners (¥ billion) | 41.7 | 27.4 | +52.4% |
| EPS (¥) | 229.64 | 147.54 | +55.6% |
| Operating margin | 1.2% | 1.3% | −0.1pp |
| Total assets (¥ billion) | 1,507.0 | 1,439.9 | +4.7% |
| Equity ratio | 33.7% | 33.5% | +0.2pp |
| Book value per share (¥) | 2,792.01 | 2,650.27 | +5.3% |
| Annual dividend (¥) | 68.00 | 63.00 | +7.9% |
| FY2027 guidance: net profit (¥ billion) | 20.8 | — | −50.2% |
JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.